Bioventus Inc
NASDAQ:BVS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.94
13.71
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Bioventus Inc
Gross Profit
Bioventus Inc
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bioventus Inc
NASDAQ:BVS
|
Gross Profit
$328.2m
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Haemonetics Corp
NYSE:HAE
|
Gross Profit
$735.3m
|
CAGR 3-Years
19%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Gross Profit
$769.1m
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
18%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Gross Profit
$2.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
17%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Gross Profit
$969.6m
|
CAGR 3-Years
78%
|
CAGR 5-Years
41%
|
CAGR 10-Years
25%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Gross Profit
$620.9m
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
Bioventus Inc
Glance View
Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 1,200 full-time employees. The company went IPO on 2021-02-11. The firm is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone.
See Also
What is Bioventus Inc's Gross Profit?
Gross Profit
328.2m
USD
Based on the financial report for Dec 31, 2023, Bioventus Inc's Gross Profit amounts to 328.2m USD.
What is Bioventus Inc's Gross Profit growth rate?
Gross Profit CAGR 5Y
7%
Over the last year, the Gross Profit growth was -1%. The average annual Gross Profit growth rates for Bioventus Inc have been 12% over the past three years , 7% over the past five years .
You don't have any saved screeners yet
